http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Upstream+Bio+to+Present+at+the+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference/26595232.html <p>WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tRVLQN0jLVVARBHk3YYp45i6J1bnmNJsTzp5xMQoh2f0j9FJlbmiJZwSk4MuLc629UGwV4H46wimQ1Za4E5Bg7B7rvRKTjLbhd_OnB1YdOY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET.</p> <p>A live webcast of the presentation will be available under the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=3d0YZBMzg8zXGwH6sEW1bxBfc-2lgBoITewxgVTKXKn4q4ezproSeqF2ISN6hHnAjCK0fwR_dNITS3XWBGQvMjr8686crdIPpms53cN5qJ_3MEDBhT1rljX0PwHggUFc" rel="nofollow" target="_blank">Events</a> tab on the Investors section of Upstream Bio’s website on the day of the http://www.streetinsider.com/Press+Releases/Upstream+Bio+to+Present+at+the+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference/26595232.html Wed, 03 Jun 2026 07:00:00 -0400 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+to+Present+at+the+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference/26595232.html <p>WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tRVLQN0jLVVARBHk3YYp45i6J1bnmNJsTzp5xMQoh2f0j9FJlbmiJZwSk4MuLc629UGwV4H46wimQ1Za4E5Bg7B7rvRKTjLbhd_OnB1YdOY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET.</p> <p>A live webcast of the presentation will be available under the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=3d0YZBMzg8zXGwH6sEW1bxBfc-2lgBoITewxgVTKXKn4q4ezproSeqF2ISN6hHnAjCK0fwR_dNITS3XWBGQvMjr8686crdIPpms53cN5qJ_3MEDBhT1rljX0PwHggUFc" rel="nofollow" target="_blank">Events</a> tab on the Investors section of Upstream Bio’s website on the day of the http://www.streetinsider.com/Press+Releases/Upstream+Bio+to+Present+at+the+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference/26595232.html Wed, 03 Jun 2026 07:00:00 -0400 O.68988411 UPB http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+to+Present+at+the+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference/26595232.html <p>WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tRVLQN0jLVVARBHk3YYp45i6J1bnmNJsTzp5xMQoh2f0j9FJlbmiJZwSk4MuLc629UGwV4H46wimQ1Za4E5Bg7B7rvRKTjLbhd_OnB1YdOY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET.</p> <p>A live webcast of the presentation will be available under the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=3d0YZBMzg8zXGwH6sEW1bxBfc-2lgBoITewxgVTKXKn4q4ezproSeqF2ISN6hHnAjCK0fwR_dNITS3XWBGQvMjr8686crdIPpms53cN5qJ_3MEDBhT1rljX0PwHggUFc" rel="nofollow" target="_blank">Events</a> tab on the Investors section of Upstream Bio’s website on the day of the http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+to+Present+at+the+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference/26595232.html Wed, 03 Jun 2026 07:00:00 -0400 O.68988411 UPB http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+to+Present+at+the+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference/26595232.html <p>WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tRVLQN0jLVVARBHk3YYp45i6J1bnmNJsTzp5xMQoh2f0j9FJlbmiJZwSk4MuLc629UGwV4H46wimQ1Za4E5Bg7B7rvRKTjLbhd_OnB1YdOY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET.</p> <p>A live webcast of the presentation will be available under the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=3d0YZBMzg8zXGwH6sEW1bxBfc-2lgBoITewxgVTKXKn4q4ezproSeqF2ISN6hHnAjCK0fwR_dNITS3XWBGQvMjr8686crdIPpms53cN5qJ_3MEDBhT1rljX0PwHggUFc" rel="nofollow" target="_blank">Events</a> tab on the Investors section of Upstream Bio’s website on the day of the http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+to+Present+at+the+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference/26595232.html Wed, 03 Jun 2026 07:00:00 -0400 O.68988411 UPB http://www.streetinsider.com/New+Coverage/H.C.+Wainwright+Starts+Upstream+Bio+%28UPB%29+at+Buy/26594630.html <p>H.C. Wainwright analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ: UPB) with a Buy rating and a price target of $36.00.</p><p>The analyst comments "What’s new? Building on positive Phase 2 trials for both severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), lead biologic candidate verekitug reflects a novel antibody antagonist of the thymic stromal lymphopoietin (TSLP) receptor, characterized in airway inflammation as an important driver of the inflammatory response in allergic and inflammatory disease. As severe asthma and CRSwNP patients remain uncontrolled despite standard treatments including FDA-approved biologics, we highlight the respective persistence of asthma flares, nasal polyp http://www.streetinsider.com/New+Coverage/H.C.+Wainwright+Starts+Upstream+Bio+%28UPB%29+at+Buy/26594630.html Wed, 03 Jun 2026 06:00:36 -0400 UPB http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Starts+Upstream+Bio+%28UPB%29+at+Buy/26594630.html <p>H.C. Wainwright analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ: UPB) with a Buy rating and a price target of $36.00.</p><p>The analyst comments "What’s new? Building on positive Phase 2 trials for both severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), lead biologic candidate verekitug reflects a novel antibody antagonist of the thymic stromal lymphopoietin (TSLP) receptor, characterized in airway inflammation as an important driver of the inflammatory response in allergic and inflammatory disease. As severe asthma and CRSwNP patients remain uncontrolled despite standard treatments including FDA-approved biologics, we highlight the respective persistence of asthma flares, nasal polyp http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Starts+Upstream+Bio+%28UPB%29+at+Buy/26594630.html Wed, 03 Jun 2026 06:00:36 -0400 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html <p>Upstream Bio Inc. (NASDAQ: UPB) presented data from its Phase 2 VIBRANT trial showing that verekitug improved asthma symptom control in participants with chronic rhinosinusitis with nasal polyps and comorbid asthma. The data was presented at the American Thoracic Society 2026 International Conference in Orlando.</p> <p>Among participants with comorbid asthma, verekitug 100 mg administered every 12 weeks led to a placebo-adjusted reduction in the Asthma Control Questionnaire-6 score of -0.9 at Week 24, compared with placebo. The reduction exceeded the minimal clinically important change threshold of -0.5.</p> <p>The VIBRANT trial included 81 participants, with approximately 60% having comorbid asthma. Verekitug also demonstrated http://www.streetinsider.com/FDA/Upstream+Bio+shows+verekitug+improves+asthma+control+in+nasal+polyp+study/26512114.html Mon, 18 May 2026 11:30:13 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html <p align="center"><em>– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –</em></p> <p align="center"><em>– Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers –</em></p> <p align="left">WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gaQWePpqb-nCCN9sUHIywlfsZSGeaB8SKCmwxuzKk--H9ys9cYaxeHTrGlwstXGsVxeS9CGNo5Ysq3MmwhpLr6Jk_3yyEqaCEzl0CUuA92U=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on http://www.streetinsider.com/Press+Releases/Upstream+Bio+Presents+New+Data+from+Phase+2+VIBRANT+Trial+of+Verekitug+Demonstrating+Improvement+in+Asthma+Symptom+Control+in+Participants+with+CRSwNP+and+Comorbid+Asthma+at+the+ATS+2026+International/26512111.html Mon, 18 May 2026 11:30:00 -0400 A.06611521 A.06822034 A.15804685 A.60012014 O.00638181 O.02021362 O.12446683 O.20026344 O.68988411 UPB